Kyverna director files initial Form 3

Kyverna Therapeutics, Inc. director Emany Sravan Kumar filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 02/26/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. director Emany Sravan Kumar filed an initial ownership report on Form 3. The filing identifies Kumar as a director of Kyverna but does not list any transactions or report any share purchases, sales, acquisitions, or dispositions at this time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Kyverna Therapeutics (KYTX) Form 3 filing show?

The Form 3 shows that Emany Sravan Kumar is a director of Kyverna Therapeutics, Inc. It is an initial statement of beneficial ownership and, in this case, reports no associated transactions or share movements for the reporting person.

Who is the reporting person in the Kyverna Therapeutics (KYTX) Form 3?

The reporting person is Emany Sravan Kumar, identified in the filing as a director of Kyverna Therapeutics, Inc. The Form 3 establishes his status as an insider subject to ongoing ownership reporting requirements under U.S. securities regulations.

Are any share transactions reported in the Kyverna Therapeutics (KYTX) Form 3?

No share transactions are reported in this Form 3. The transactions section is empty and summary counts for buys, sells, acquisitions, and dispositions all show zero, indicating no reported trades or ownership changes associated with this initial filing event.

Does the Kyverna Therapeutics (KYTX) Form 3 indicate buying or selling activity?

The filing indicates no buying or selling activity. All transaction counts, including buy, sell, acquire, and dispose, are recorded as zero, and the net buy/sell direction is described as neutral, reflecting the absence of reported trades.

What is the purpose of Emany Sravan Kumar’s Form 3 for Kyverna Therapeutics (KYTX)?

The purpose is to provide an initial ownership statement for an insider of Kyverna Therapeutics, Inc. It formally records Kumar’s status as a director and sets a baseline for any future ownership changes that would be disclosed in subsequent Forms 4 or 5.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Emany Sravan Kumar

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/24/2026

3. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Marc Grasso, as Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.